美國居民不適用 XM 服務。
A
A

Amgen

財經新聞

Amgen Inc Says CEO Robert Bradway's 2023 Total Compensation Was $22.6 Million Versus $21.4 Million In 2022 – SEC Filing

BRIEF-Amgen Inc Says CEO Robert Bradway's 2023 Total Compensation Was $22.6 Million Versus $21.4 Million In 2022 – SEC Filing April 17 (Reuters) - Amgen Inc AMGN.O : AMGEN INC SAYS CEO ROBERT A. BRADWAY'S 2023 TOTAL COMPENSATION WAS $22.6 MILLION VERSUS $21.4 MILLION IN 2022 – SEC FILING Source text for Eikon: [ID: https://bitly.ws/3idLq ] Furt
A

U.S. 3M, J&J, Nuvalent

U.S. RESEARCH ROUNDUP-3M, J&J, Nuvalent April 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including 3M, J&J and Nuvalent, on Wednesday. HIGHLIGHTS * 3M Co MMM.N : JP Morgan cuts target price to $110 from $118 * J&J JNJ.N : RBC cuts target price to $175 from $181 * Nuvalent Inc NUVL.O : Jefferies initiates coverage with buy rating; price target $97 * Tractor Supply Co TSCO.O : Barclays raises target price to $234 from $1
A
A
A
B
B
C
G
J
I
A
C
F

Amgen Planning Underway For Phase 3 Development Of tezepelumab In COPD

BRIEF-Amgen Planning Underway For Phase 3 Development Of tezepelumab In COPD April 16 (Reuters) - Amgen Inc AMGN.O : AMGEN INC - PLANNING UNDERWAY FOR PHASE 3 DEVELOPMENT OF TEZEPELUMAB IN COPD Source text for Eikon: ID:nPn24LPZYa Further company coverage: AMGN.O
A

U.S. Advanced Micro Devices, Kroger, Tyson Foods

U.S. RESEARCH ROUNDUP-Advanced Micro Devices, Kroger, Tyson Foods April 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Advanced Micro Devices, Kroger and Tyson Foods, on Tuesday. HIGHLIGHTS * Advanced Micro Devices Inc AMD.O : HSBC raises to buy * CNO Financial Group Inc CNO.N : Piper Sandler raises to overweight from neutral * Endeavor Group Holdings Inc EDR.N : Citigroup cuts to neutral from buy * Kroger Co KR.
A
A
B
B
C
C
G
G
I
N
S
A
A
K
L
A
C
C
C
M

Neumora Therapeutics falls after US FDA puts schizophrenia drug study on hold

BUZZ-Neumora Therapeutics falls after US FDA puts schizophrenia drug study on hold ** Shares of drug developer Neumora Therapeutics NMRA.O fall 22.5% to $10.51 premarket ** Co says the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the early-stage study of its schizophrenia drug candidate ** Schizophrenia is a serious mental
A

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明